Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive breast cancer data for Kisqali

Novartis reports positive breast cancer data for Kisqali

8th November 2017

Novartis has announced the findings of a new clinical trial demonstrating the benefits its drug Kisqali can offer for people with advanced breast cancer.

Positive topline results have been announced from the global MONALEESA-7 trial, showing that Kisqali combination therapy was able to deliver progression-free survival benefits in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer.

Kisqali is the first CDK4/6 inhibitor to be studied in a phase III global trial exclusively focusing on premenopausal women with this form of cancer. MONALEESA-7 is also the first study to demonstrate the superiority of a CDK4/6 inhibitor in combination with hormonal therapies and goserelin over endocrine treatment in this patient population in more than 20 years.

Samit Hirawat, executive vice-president and head of global drug development at Novartis Oncology, said: "There remains a significant unmet treatment need in younger women diagnosed with premenopausal advanced breast cancer, as the disease tends to be more aggressive with a poorer prognosis."

This was the second phase III trial of Kisqali in advanced or metastatic breast cancer, with Novartis planning to begin discussions of the results with global health authorities worldwide in the near future.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.